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to-moderate bleeds in a hemophilia patient with inhibitors is very
high. When considering the impact of rebleeding over multiple
lines of treatment, the rFVIIa-only regimen, versus APCC-con-





COSTS AND CONSEQUENCES OF INADEQUATE
COMPLIANCE WITH DEFEROXAMINE THERAPY IN PATIENTS
WITH TRANSFUSION-DEPENDENT THALASSEMIA
Delea T1, Sofrygin O1,Thomas S2, Baladi JF3, Coates TD4, Phatak P5
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2Novartis
Pharmaceuticals Corp, East Hanover, NJ, USA, 3Novartis
Pharmaceuticals Corp, Florham Park, NJ, USA, 4Childrens Hospital of
Los Angeles, Los Angeles, CA, USA, 5Rochester General Hospital,
Rochester, NY, USA
OBJECTIVES: Patients with transfusion-dependent thalassemia
require chelation to prevent complications from transfusional
iron overload. Deferoxamine (DFO) is an effective iron chelator,
but must be administered as a subcutaneous or intravenous infu-
sion over 8–12 hours 5–7 times per week leading to poor com-
pliance and/or quality of life in many patients. METHODS: We
developed a Markov model using data from published studies
and other sources to estimate the lifetime incidence and medical
care costs of complications of iron overload that are attributable
to inadequate compliance with DFO therapy in patients with
transfusion-dependent thalassemia. Complications considered
included cardiac disease, diabetes, hypogonadism, hypoparathy-
roidism, hypothyroidism, and death due to cardiac disease.
Current compliance with DFO therapy as well as costs of com-
plications were obtained from an analysis of health insurance
claims data. Adequate compliance was deﬁned as 260 infusions
per year (i.e., ﬁve per week). Costs were discounted at 3% annu-
ally. RESULTS: Current mean DFO use was estimated to be 169
infusions annually. At this level of compliance, 95% of patients
are projected to experience cardiac disease during their lifetime,
diabetes 46%, hypogonadism 77%, hypoparathyroidism 32%,
and hypothyroidism 26%. Cardiac-disease-free life expectancy is
projected to be 23 years; overall life expectancy, 28 years. The
expected lifetime cost of complications of iron overload is
$54,151 per patient. If mean compliance were to increase to 260
infusions per year, the lifetime risk of cardiac disease would
decline to 60%, diabetes to 9%, hypogonadism to 47%, and
hypothyroidism to 14%. Cardiac-disease-free and overall life
expectancy would increase by 22 and 19 years respectively. The
discounted expected lifetime costs of complications of iron over-
load would decline by $30,222. CONCLUSIONS: Inadequate
compliance with DFO therapy in patients with transfusion-
dependent thalassemia results in substantial morbidity and 
mortality, as well as increased medical care costs associated with
complications of iron overload.
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OBJECTIVES: Haemophilia is a very expensive disease. This sit-
uation becomes extreme when patients develop inhibitors that
compromise the effectiveness of treatment, with potential
increase of morbidity and mortality. Treatment of haemophilia
is the result of interactions between patients, physicians, phar-
macists and budget holders, each carrying their own set of 
preferences. A pilot study was conducted to identify which char-
acteristic of coagulation products are considered more important
to treat patients with inhibitors: these characteristics will be
included with a price proxy characteristic in a Discrete Choice
Experiment, with the objective to elicit preferences and willing-
ness to pay towards treatments of patients with inhibitors.
METHODS: Eight characteristics were identiﬁed during focus
groups with patients and clinicians and rated from 0 (not impor-
tant) to 10 (very important) by 35 people (adult patients, care-
givers, physicians, pharmacists). RESULTS: the following
median (mean) scores were found: “viral safety”: 10 (8.9); “time
to stop bleeding”: 9.5 (9.0); “risk of anamnestic response”: 9.0
(8.5); “possibility of undergoing major surgery”: 9.0 (8.8);
“regular use in prophylaxis”: 9.0 (8.4); “time to pain recovery”:
9.0 (8.3); “number of injections to stop bleeding”: 8.0 (7.9);
“time to prepare and give/have the injection”: 7.0 (6.6). All
groups of respondents considered as more important “viral
safety”, “possibility of undergoing major surgery”, “risk of
anamnestic response”, “time to stop bleeding”, while “time to
prepare and give/have the injection” was considered the least
important. Different preferences were attributed to “time to pain
recovery”, considered more important by patients; “regular use
in prophylaxis”, considered more important by caregivers.
CONCLUSIONS: Viral safety and effectiveness are considered
as the most important characteristics in the treatment of
haemophilic patients with inhibitors. Different levels of prefer-
ences are present between patients, or their caregivers, and physi-
cians. Understanding these differences is important to guide
optimal therapeutic strategies in patients with inhibitors.
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OBJECTIVE: To determine and quantify the unique character-
istics of clinical trial participants in comparison to the general
patient population. METHODS: Data were obtained from the
U.S. National Health and Wellness Survey, an annual, nationally
representative, Internet-based study of the health care attitudes
and behaviors of non-institutionalized adults age 18+. The
sample for analysis included 18,419 respondents who reported
a diagnosis of hypertension, high cholesterol, or diabetes.
Respondents reported ever participating in a clinical drug trial.
They also provided information on demographics, healthcare
attitudes, health habits, quality of life measured by the SF-8, and
healthcare resource use in the past six months. RESULTS:
Among respondents diagnosed with hypertension, high choles-
terol, or diabetes, 7% (n = 1333) have participated in a clinical
drug trial. Clinical trial participants signiﬁcantly differ from the
general patient population in many key characteristics. Clinical
trial participants are signiﬁcantly older (mean age 60.5 versus
55.1, p < 0.001) and more educated (college graduates 43%
versus 36%, p < 0.001). They experience worse physical well-
being (sf-8 physical component summary score 43.1 versus 45.3,
p < 0.001), though are more likely to maintain a healthy diet
(50% versus 46%, p = 0.002) and less likely to smoke (18%
versus 23%, p < 0.001). Clinical trial participants are more
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willing to use alternative therapy such as acupuncture (49%
versus 43%, p < 0.001) and more likely to visit an alternative
provider (32% versus 24%, p < 0.001). They are also more likely
to visit a traditional provider (96% versus 92%, p < 0.001) and
do so with greater frequency (visits 7.2 versus 5.6, p < 0.001)
than the general patient population. CONCLUSION: Clinical
trial participants are unique individuals who differ from those in
the general patient population. Therefore, the treatment experi-
ences of clinical trial participants may not always be predictive
of the treatment experiences of the general patient population.
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OBJECTIVES: The purpose of this study was to assess the
overall experience of members enrolled in Consumer Choice
Pharmacy (CCP). CCP is an innovative three-level prescription
beneﬁt plan based on consumer-driven models (Level 1: Phar-
macy account; Level 2: Employee Responsibility; Level 3: 
Traditional Coinsurance). The goal of this program is to assist
members in making more informed personal pharmacy deci-
sions, while contributing to the plan sponsors cost-containment
efforts. METHODS: In April 2005, a survey was mailed to all
member households of an employer group enrolled in CCP to
assess knowledge, perception, satisfaction, and overall experi-
ence with the plan. Response frequencies and means were cal-
culated. Statistical differences in responses based on member
characteristics and pharmacy utilization were also evaluated.
RESULTS: A total of 925 surveys were mailed. Of these, 100
(11%) were returned. Respondents and non-respondents had
similar demographic characteristics, but were different in terms
of pharmacy utilization and spending, with respondents having
both higher utilization and spending. Respondents indicated the
potential to save money was the most inﬂuential factor in their
decision to enroll in the plan. A large proportion of respondents
had a good (30%), very good (29%), or excellent (10%) under-
standing of CCP. Seventy-eight percent indicated that CCP met
or exceeded their expectations. Most respondents indicated their
overall experience was good (38%), very good (13%), or excel-
lent (24%) and were satisﬁed (52%) or very satisﬁed (27%) with
the plan. Respondents with greater than three claims per month
were less satisﬁed (p = 0.004) than those with three or fewer
claims per month. Fifty-three percent would recommend the plan
to others. There were no signiﬁcant differences in overall
responses based on whether or not respondents had money
remaining in their pharmacy accounts. CONCLUSIONS: Survey
results show that respondents generally have a clear under-
standing of CCP and are satisﬁed with the program.
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OBJECTIVES: CDH beneﬁt plans use ﬁnancial incentives for
plan participants to reduce utilization of health services and are
attractive to low utilizers. This study assesses the impact of CDH
design on subsequent utilization by controlling for adverse selec-
tion with a control group. METHODS: Continuously eligible
plan participants of a pharmacy-only CDH plan were analyzed
as a study group identiﬁed through Caremark 2003–2004 phar-
macy claims and eligibility data. A control group matched to the
CDH group was drawn from the non-CDH plan participants
within the same plan sponsor, using stratiﬁed random sampling
within 8 groups based on age, health-risk index, prescription
count and gross costs. Pharmacy utilization patterns were
studied pre-to-post and compared to control. Wilcoxon rank
sums test was used to assess signiﬁcance of differences between
groups and over time, using a p-value of 0.05 for signiﬁcance.
RESULTS: The control (N = 2403) matched the CDH group (N
= 2403) in age (29.8 vs. 29.5), HRI score (4.5 vs. 3.9), and pre-
scriptions (5.0 vs. 4.6). No baseline differences were identiﬁed
(p-values from 0.1751 to 0.4564). Utilization increased between
2003 and 2004 for the control but not for the CDH group. The
CDH group increased prescriptions from 4.61 to 4.90, days’
supply from 101.89 to 111.60 and gross costs from $171.59 to
$190.55, (p = 0.7651 to 0.3501), while the control increased 
prescriptions from 5.03 to 5.99, days’ supply from 113.89 to
142.24, and gross costs from $187.56 to $253.44, (p < 0.0001).
Mail utilization increased for both but substantially more for
CDH (57% increase vs. 19%, p < 0.0001). Generic utilization
and formulary compliance did not differ. Medical costs will be
presented. CONCLUSION: The CDH beneﬁt plan limited an
increase in drug utilization as compared to the traditional plan.
Also, mail utilization increased with CDH.
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OBJECTIVES: To determine the out-of-pocket prices of outpa-
tient prescription drugs using methods that account for the mul-
timodality of their distributions. METHODS: Using data from
the 1992—2002 Medicare Current Beneﬁciary Survey and the
1996—2003 Medical Expenditure Panel Survey, we demonstrate
the multimodality of prices for 175 of the most commonly pre-
scribed medications in the United States. Through the applica-
tion of Gaussian and gamma mixture models, we estimate the
cash price and covered price paid by consumer for each of these
medications, and estimate the percentage of consumers paying
each price. RESULTS: The results suggest that simple averages
of out-of-pocket prices are not applicable for economic evalua-
tions and policy studies in pharmaceutical economics, except in
the case of multisource medications. Without the integration of
price disparities, analyses of single source medications may lead
to erroneous policy conclusion. CONCLUSIONS: Price dispari-
ties may have been the motivation for recent coverage expansion
endevours, such as Medicare Part D. Our results demonstrate 
the prevalence and extent of these price disparities, which 
appear particularly grave in the price distributions of branded
medications.
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